08.09.2016 • NewsDede WillamsretrosenseAllergan

Allergan Acquires Retrosense

“The acquisition of RetroSense and its RST-001 program builds on Allergans...
“The acquisition of RetroSense and its RST-001 program builds on Allergan's deep commitment to eye care and our focus on investing in game-changing innovation for retinal conditions,” said Allergan CEO Brent Saunders.

Allergan has acquired “substantially all” of the assets of RetroSense Therapeutics, a private, clinical-stage biotechnology company focused on novel gene therapy approaches to restore vision in patients suffering from blindness. Under the terms of the all-cash transaction, Allergan has paid RetroSense a $60 million upfront payment and has agreed to potential regulatory and commercialization milestone payments related to its lead development program, RST-001, being touted as a novel gene therapy for the potential treatment of Retinitis Pigmentosa (RP).

The disease belongs to a group of rare, inherited genetic disorders characterized by progressive peripheral vision loss and night vision difficulties followed by eventual central vision loss and blindness in many cases. “The acquisition of RetroSense and its RST-001 program builds on Allergan's deep commitment to eye care and our focus on investing in game-changing innovation for retinal conditions,” said Allergan CEO Brent Saunders.

RST-001, the acquired company’s first-in-class gene therapy application of optogenetics, offers a therapeutic approach that confers light sensitivity to cells that were not previously, or natively, light sensitive. In 2014, RST-001 received an Orphan Drug Designation by the US Food and Drug Administration (FDA) for the treatment of RP.

“The program and its optogenetic gene therapy approach could be a real breakthrough in the treatment of unmet needs across a host of retinal conditions, including RP,” said David Nicholson, Allergan’s chief R&D officer.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read

Photo
24.01.2025 • News

And the Winners are: Cynio, EnaDyne and Green Li-ion

The CHEManager Innovation Pitch, the start-up promotion initiative of CHEManager and CHEManager International, has given more than 100 start-ups from over 15 countries the opportunity to present their innovative ideas, products and technologies to a broad target group since its launch in 2019.

Photo
19.03.2025 • NewsInnovation

Data-Driven Enzyme Immobilization

Inseit, based in Bern, develops biocatalysts for industrial setups using enzyme immobilization and biocomputation. Addressing biotech and sustainability challenges, Inseit was selected for Venture Leaders Biotech and won two Nucleate accelerator prizes.

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.